📊 PRME Key Takeaways
Is Prime Medicine, Inc. (PRME) a Good Investment?
Prime Medicine is an early-stage biotech company with strong revenue growth (+55.3% YoY) and improving EPS trends, but is severely unprofitable with operating losses of -$50.7M against only $4.6M revenue and significant cash burn of -$42.7M annually. While the company maintains strong liquidity (3.80x current ratio) and zero debt, providing ~1.5 years of runway, there is no demonstrated path to profitability and financial fundamentals indicate unsustainable unit economics at current scale.
Prime Medicine, Inc. Key Strengths (PRME)
- Revenue growth of 55.3% YoY demonstrates product market traction and commercial execution
- Strong balance sheet with $64.1M cash and zero long-term debt provides financial flexibility
- Improving diluted EPS (+18.2% YoY) shows operating leverage beginning to develop
- Excellent liquidity position (3.80x current ratio) eliminates near-term solvency risk
PRME Stock Risks: Prime Medicine, Inc. Investment Risks
- Severe unprofitability with -$1,093.6% operating margin and -$1,060.5% net margin indicates business model challenges
- Annual cash burn of $42.7M against $4.6M revenue is unsustainable without exponential growth acceleration or profitability inflection
- Runway of approximately 1.5 years based on current burn rate and cash position creates existential timeline pressure
- Early revenue base ($4.6M) represents minimal revenue scale relative to operating cost structure
- Operating losses dwarf revenue by >10x, requiring dramatic margin expansion for viability
Key Metrics to Watch
- Quarterly revenue growth trajectory and absolute revenue scale to assess if growth sustains momentum
- Operating cash burn rate and path to cash flow breakeven relative to cash runway
- Operating margin improvement trend to validate inflection toward sustainable unit economics
Prime Medicine, Inc. (PRME) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.80x current ratio provides a solid financial cushion.
PRME Profit Margin, ROE & Profitability Analysis
PRME vs Healthcare Sector: How Prime Medicine, Inc. Compares
How Prime Medicine, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Prime Medicine, Inc. Stock Overvalued? PRME Valuation Analysis 2026
Based on fundamental analysis, Prime Medicine, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Prime Medicine, Inc. Balance Sheet: PRME Debt, Cash & Liquidity
PRME Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Prime Medicine, Inc.'s revenue has declined by 11% over the 5-year period, indicating business contraction. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
PRME Revenue Growth, EPS Growth & YoY Performance
PRME Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $209.0K | -$45.8M | $-0.32 |
| Q2 2025 | N/A | -$45.8M | $-0.41 |
| Q1 2025 | $591.0K | -$45.8M | $-0.40 |
| Q3 2024 | N/A | -$39.4M | $-0.44 |
| Q2 2024 | N/A | -$39.4M | $-0.46 |
| Q1 2024 | N/A | -$39.4M | $-0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Prime Medicine, Inc. Dividends, Buybacks & Capital Allocation
PRME SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Prime Medicine, Inc. (CIK: 0001894562)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRME
What is the AI rating for PRME?
Prime Medicine, Inc. (PRME) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRME's key strengths?
Claude: Revenue growth of 55.3% YoY demonstrates product market traction and commercial execution. Strong balance sheet with $64.1M cash and zero long-term debt provides financial flexibility.
What are the risks of investing in PRME?
Claude: Severe unprofitability with -$1,093.6% operating margin and -$1,060.5% net margin indicates business model challenges. Annual cash burn of $42.7M against $4.6M revenue is unsustainable without exponential growth acceleration or profitability inflection.
What is PRME's revenue and growth?
Prime Medicine, Inc. reported revenue of $4.6M.
Does PRME pay dividends?
Prime Medicine, Inc. does not currently pay dividends.
Where can I find PRME SEC filings?
Official SEC filings for Prime Medicine, Inc. (CIK: 0001894562) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRME's EPS?
Prime Medicine, Inc. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PRME's fundamental grade?
Based on our AI fundamental analysis in May 2026, Prime Medicine, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PRME stock overvalued or undervalued?
Valuation metrics for PRME: ROE of -64.0% (sector avg: 15%), net margin of -1,060.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PRME's AI grade for 2026?
Our dual AI analysis gives Prime Medicine, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRME's free cash flow?
Prime Medicine, Inc.'s operating cash flow is $-42.7M, with capital expenditures of $214.0K. FCF margin is -926.7%.
How does PRME compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,060.5% (avg: 12%), ROE -64.0% (avg: 15%), current ratio 3.80 (avg: 2).